Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Dapagliflozin Taken Twice-daily

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* Diagnosis of T2DM~* Current antihyperglycaemic treatment with metformin immediate release formulation monotherapy \>/= 1500 mg/day at a stable dose for at least 10 weeks prior to enrolment. Other treatment with OADs within the 10 weeks prior to enrolment is not permitted.~* HbA1c ≥ 6.7% and ≤10.5%, based on central laboratory values from Screening Visit, and Enrolment Visit 1.~Exclusion Criteria:~* Diagnosis of Type 1 diabetes mellitus, known diagnosis of Maturity Onset Diabetes of the Young (MODY) or secondary causes of diabetes mellitus~* History of diabetic ketoacidosis~* Symptoms of poorly controlled diabetes including, but not limited to, marked polyuria, polydipsia, and/or greater than 10% weight loss during the 3 months prior to enrolment~* FPG \>270 mg/dL (\>15.0 mmol/L)~* BMI \>45 kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Dapagliflozin 2.5 mg twice-daily plus open-label metformin
- 2 (Type: EXPERIMENTAL): Dapagliflozin 5.0 mg twice-daily plus open-label metformin
- 3 (Type: EXPERIMENTAL): Dapagliflozin 10 mg once-daily plus open-label metformin
- 4 (Type: PLACEBO_COMPARATOR): Placebo plus open-label metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).